Moderna’s early-stage human trial for a coronavirus vaccine produced Covid-19 antibodies in all 45 participants, the biotech company announced Monday.
“These data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19,” Moderna chief medical officer Dr. Tal Zaks said in a statement.
– Upon the news, the company’s shares surged more than 20%.
Each participant received a 25, 100 or 250 microgram dose, with 15 people in each dose group. Participants received two doses of the potential vaccine via injection in the upper arm approximately 28 days apart.
The potential vaccine contains genetic material called messenger RNA, or mRNA. The mRNA is a genetic code that tells cells what to build — in this case, an antigen that may induce an immune response to the virus.
The company said the vaccine was generally safe and well-tolerated in the phase 1 trial. If the vaccine is found to be effective and safe to use, it could be ready for the market in early 2021.